EpileaseEpilease, an anti-epileptic therapy product, is back on the market following official licensing from the VMD.

The product comes from veterinary nutraceutical expert VetPlus and contains potassium bromide, a well-established adjunctive treatment for epilepsy in dogs.

VetPlus halted the mass circulation of the product in 2011, but has now reintroduced Epilease 250mg, with the same formulation, in a blister pack of 60 capsules.


Phillipa Lomax, senior marketing manager at VetPlus, said: “Epilease is a trusted treatment for thousands of dog owners worldwide, so we are pleased to announce it is back on the market.

“We are now able to offer another treatment option, thereby improving not only seizure management in canine patients, but also aiding dogs’ and owners’ quality of life.”

View your activity >

Leave a Reply

Be the First to Comment!

Notify of


related content

A former shopping centre plant room that has been transformed into a state-of-the-art surgery marks a milestone for an expanding veterinary group.

3 mins

Kelly Bowlt Blacklock looks at studies on companion animal wound care, focusing on emerging techniques (part 1/2).

12 mins

RVN Emma Gerrard looks at the common endocrinopathies that present in practice and how nurses can involve their clients in helping to manage these conditions.

27 mins

SVN Simon Johnson discusses the preconceptions he faces as a man in a predominately female profession and how this can be addressed in the future.

18 mins

CVS Group has appointed Belinda Andrews-Jones to its newly created role of director of nursing. Dan Curtis of Pet Medic Recruitment speaks with her about this and her career to date.

16 mins

Suzanne Rogers reports on the results and feedback from a questionnaire with owners at the annual event held in Cumbria.

18 mins